Climate Change Data

Angelini Pharma S.p.A.

Climate Impact & Sustainability Data (2022, 2023)

Reporting Period: 2022

Environmental Metrics

Total Carbon Emissions:15,036.8 tCO2e/year (Scope 1 and 2)
Scope 1 Emissions:15,036.8 tCO2e/year
Scope 2 Emissions:9,418.7 tCO2e/year (market-based) / 7,677.5 tCO2e/year (location-based)
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:255,195.3 GJ/year (fuel consumption)
Water Consumption:881.8 megaliters/year (withdrawal)
Waste Generated:10,972.0 tons/year
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Economic
  • Environmental
  • Social
  • Governance

Environmental Achievements

  • Reduction of consumption at the production plants equal to 1,627 toe of energy, corresponding to 3,172 tCO2eq
  • Self-production through photovoltaic energy equal to 443 GJ and consequent avoided atmospheric emissions equal to around 41 tCO2eq
  • Ancona facility recorded a value of 0.73 m3 of water withdrawn per piece produced, a 14% decrease compared to 2021

Social Achievements

  • Creation of the Global Manifesto for Diversity and Inclusion and a Diversity & Inclusion Team with ambassadors from every function/geographical area
  • Around 150,000 total hours of technical training and various initiatives for the development of managerial skills (Angelini Academy and My Development Garden)
  • 370 new hires, of which 56% women and 21% aged under 30
  • Internal fundraising campaign and donation of 100,000 packs of anti-inflammatory drugs and paracetamol to support Ukraine
  • Supported the EBRI Foundation project to welcome female students from Afghanistan to Rome

Governance Achievements

  • Adoption of the Code of Ethics of the Parent Company Angelini Holding S.p.A.
  • Implementation of an Organization, Management and Control Model in line with Legislative Decree 231/2001
  • Establishment of internal whistleblowing channels

Climate Goals & Targets

Long-term Goals:
  • Not disclosed
Medium-term Goals:
  • Not disclosed
Short-term Goals:
  • Not disclosed

Environmental Challenges

  • Uncertainty and complexity in the market due to the continuing effects of the Covid-19 pandemic and Russia’s invasion of Ukraine, leading to increased costs and potential shortages of raw materials
  • Combating antibiotic resistance
Mitigation Strategies
  • Implementation of a three-phase risk management system for supply chain management (risk assessment, risk management, recalculation of risk coefficient)
  • Awareness-raising program to promote sensible prescription practices and the appropriate use of antibacterials
  • Investment in clean energy production and energy efficiency measures (smart energy information platform, optimized cooling curves, air treatment systems, replacement of production machines)

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement
  • Adoption of the company’s Code of Ethics
  • Compliance with ethical criteria and regulatory requirements
  • Use of the Group e-Procurement system (Procunity)

Climate-Related Risks & Opportunities

Physical Risks
  • Not disclosed
Transition Risks
  • Not disclosed
Opportunities
  • Not disclosed

Reporting Standards

Frameworks Used: GRI Universal Standards (October 5, 2021), 2013 GBS Standard

Certifications: UNI EN ISO 9001:2015, UNI EN ISO 13485:2016, UNI EN ISO 14001:2015, UNI ISO 45001:2018, FDA (Albany plant), ISO 13485 (Albany plant), TÜV (Albany plant)

Third-party Assurance: BDO Italia S.p.A.

UN Sustainable Development Goals

  • Not disclosed

Not disclosed

Sustainable Products & Innovation

  • Not disclosed

Awards & Recognition

  • Third place in AboutPharma Digital Awards (Best Digital Company)
  • First place in AboutPharma Digital Awards (Best Social Company)
  • Top Employer Italy and Top Employer Europe

Reporting Period: 2023

Environmental Metrics

Total Carbon Emissions:16,773.3 tCO2eq (Scope 1 & 2)
Scope 1 Emissions:15,059.6 tCO2eq
Scope 2 Emissions:6,204.9 tCO2eq (market-based)
Scope 3 Emissions:Not disclosed
Renewable Energy Share:Not disclosed
Total Energy Consumption:335,376.8 GJ
Water Consumption:52.0 megaliters
Waste Generated:11,731.53 tons
Carbon Intensity:Not disclosed

ESG Focus Areas

  • Planet
  • People
  • Patients & Community
  • Ecosystems
  • Product Innovation
  • Governance

Environmental Achievements

  • Reduced total water withdrawal by 10% (2023 vs 2022)
  • Achieved a 29% increase in waste directed to recycling, reuse and recovery (2023 vs 2022)
  • Launched carbon footprint calculation
  • Started Life Cycle Assessment process on five brands
  • Participation in LIFE-GREENAPI project to find more innovative and environmentally friendly ways to produce active pharmaceutical ingredients
  • Ancona plant recorded a value of 28.87 toe/million pieces produced, a 28.4% decrease compared to 2022

Social Achievements

  • Obtained UNI/PdR 125:2022 certification for gender equality in Italy (50% female composition of the global workforce)
  • Achieved Top Employer certification for the fourth consecutive year
  • Launched #STOBENEGRAZIE campaign to raise awareness and combat stigma associated with depression
  • Launched We Care project to expand and enhance welfare offer for all employees
  • Implemented flexible working policy, granting 100 flexible days annually

Governance Achievements

  • Adopted a Corporate Governance Model aligned with best market practices
  • Implemented an Organization, Management and Control Model to prevent offences as referred to in Italian Legislative Decree 231/2001
  • Obtained certification of compliance with Farmindustria guidelines for scientific information activities and Code of Ethics
  • UNI EN ISO 14001:2015 (Environmental Management System) and UNI EN ISO 45001:2018 (Occupational Health and Safety) certified for three Italian production sites

Climate Goals & Targets

Long-term Goals:
  • Climate: Reduce GHG emissions in line with Paris Agreement by 2030
Medium-term Goals:
  • Climate: 100% renewable purchased electricity (Italy) by 2024
  • Climate: 100% renewable purchased electricity on climate change (all Angelini Pharma) by 2026
  • Waste & circularity: -90% industrial waste to landfill by 2028
  • Waste & circularity: 100% new products rolled out / EcoDesign considerations by 2030
  • Well-being: Engagement rate ≥75 by 2030
  • H&S: Zero serious injuries ambition for own employees by 2030
  • Incentives (cross): 100% N-1 and N-2 MBOs linked to ESG indicators by 2030
  • Development: Training hours/ employee > European sector average by 2030
  • Local Communities: +20% each year of employees volunteering for local communities by 2030
  • Top Employer: remain top employer in Italy and Europe and be part of top companies in Best Workplaces Europe by 2030
  • Local Communities and Ecosystem: Be a recognized partner to promote transition to future skills and contribute to closing the knowledge gap in the Italian system by 2030
  • Health awareness and access to care: Be an accelerator of awareness & de-stigmatization to unlock access to care by 2030
  • Partner with value chain: >90% strategic suppliers covered by Code of Conduct by 2030
  • Embed responsible procurement: >90% strategic suppliers assessed on ESG criteria (by 2027) by 2030
Short-term Goals:
  • Not disclosed

Environmental Challenges

  • 7% increase in total waste produced despite increase in recycling
  • Increased direct emissions (Scope 1) of 11.5% due to increased fuel consumption
  • Potential unethical business practices
  • Loss of margins due to unexpected/unmanaged disruptions in the value chain
  • Loss of/reduced attractiveness to talent due to failure to ensure equality for all
  • Potential unethical business practices (e.g., in animal welfare, lack of transparency in marketing) with market and/or regulatory repercussions
  • Failure to apply adequate due diligence measures, resulting in human rights violations within the corporate value chain (child/forced labor)
  • Inability to address new potential pandemics, originating from neglected tropical diseases (NTDs) and/or other potential widespread dangerous diseases, through adequate resources and R&D strategies
  • Lawsuits and product recalls due to unwanted/unexpected side effects and/or unsafe levels of hazardous ingredients
  • Negative effects on the health resilience of communities due to the intake of pharmaceutical substances
  • Disadvantages for communities caused by the organization’s production activities
Mitigation Strategies
  • Implemented measures to mitigate production process impacts with high-value programs, such as LIFE-GREENAPI
  • Implemented a corruption risk management system, including training and awareness initiatives for employees and business partners
  • Adopted an Information Security Management System (ISO/IEC 27001 certified)
  • Implemented a Compliance program to prevent and detect possible violations of competition law
  • Implemented a flexible working policy
  • Implemented a Global Manifesto for Diversity and Inclusion
  • Implemented an ESG screening project targeting 80% of total purchasing turnover
  • Implemented measures to reduce water consumption (high-efficiency cooling towers and leakage control)
  • Implemented measures to reduce waste (recycling, reuse, recovery)
  • Implemented measures to reduce energy consumption (Energy Team, energy efficiency measures based on machine learning algorithms)
  • Implemented Life Cycle Assessment (LCA) methodology on five products

Supply Chain Management

Supplier Audits: Not disclosed

Responsible Procurement
  • Code of Conduct
  • ESG performance KPIs integrated into category management
  • ESG screening project targeting 80% of total purchasing turnover

Climate-Related Risks & Opportunities

Physical Risks
  • Extreme weather events
Transition Risks
  • Regulatory changes
Opportunities
  • Development of energy-efficient products

Reporting Standards

Frameworks Used: GRI Universal Standards

Certifications: UNI/PdR 125:2022 (Gender Equality), UNI EN ISO 14001:2015 (Environmental Management System), UNI EN ISO 45001:2018 (Occupational Health and Safety), ISO 13485:2021 (Quality Management System for Medical Devices), ISO/IEC 27001 (Information Security Management System)

Third-party Assurance: EY S.p.A.

Sustainable Products & Innovation

  • 400 ml Pouch Refill packs for Infasil Intimi
  • Amuchina products packaged using 100% recycled plastic

Awards & Recognition

  • Top Employer Europe (4 consecutive years)
  • Top Employer Italy
  • Top Employer Spain, Portugal, Poland, Turkey, Germany and Romania
  • Third place in “Italy’s Best Employers” ranking
  • Best in Media Communication in Italy
  • Best Digital Company at the AboutPharma Digital Awards
  • Excellence in Scientific Information and Patient Centricity Award for EpiOnApp